Program
Doxycycline
Also written as “Doxycycline Monohydrate”, “doxycycline monohydrate” and “doxycycline”.
Its studies are mostly in Rosacea · Acne Vulgaris · Fasting · Anthrax · Diabetic Foot, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Group | 80 open or running | phase 4since Jun 29, 2007 | Jul 19, 2002 | none ahead |
| Par Health | 50 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| AbbVie | 30 open or running | phase 4since Mar 7, 2008 | Jan 25, 2008 | none ahead |
| Viatris | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Sun Pharmaceutical Industries | 20 open or running | no phasesince Oct 17, 2008 | Oct 17, 2008 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jan 26, 2009 | Jan 26, 2009 | none ahead |
| alacrity-biosciences-inc | 10 open or running | phase 2since Feb 22, 2007 | Feb 22, 2007 | none ahead |
| Dr. Reddy's Laboratories | 10 open or running | phase 2since Oct 19, 2017 | Oct 19, 2017 | none ahead |
| nanoshift-llc | 10 open or running | phase 2since Oct 1, 2008 | Oct 1, 2008 | none ahead |
| Pfizer | 10 open or running | phase 4since Jul 8, 2009 | Jul 8, 2009 | none ahead |
Also a collaborator on its studies: Almirall and anapharm.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jul 19, 2002.
- Mar 7, 2008Phase 4 study in Acne VulgarisAbbVie · NCT00635609 · 93 enrolled · United States
- Mar 30, 2008Viatris's first studies: 3 phase 1 studies in HealthyNew to ViatrisViatris · NCT00649571, NCT00648180, NCT00647959
- Apr 1, 2008Par Health's first studies: 5 phase 1 studiesNew to Par HealthPar Health · NCT01380496, NCT01380483, NCT00653380 and 2 more
- Oct 1, 2008nanoshift-llc's first study: phase 2 study in Diabetic FootNew to nanoshift-llcnanoshift-llc · NCT00764361 · 15 enrolled · United States
- Oct 17, 2008Sun Pharmaceutical Industries's first studies: 2 no phase studies in HealthyNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT00775918, NCT00775177
- Jan 26, 2009Teva Pharmaceutical Industries's first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00829790, NCT00829764
- Apr 30, 2009Phase 4 study in RosaceaGalderma Group · NCT00892281 · 1,421 enrolled · United States
- Jul 8, 2009Pfizer's first study: phase 4 study in Bacterial InfectionsNew to PfizerPfizer · NCT00939562 · 24 enrolled · India
- Apr 28, 2010Phase 3 study in Chlamydia InfectionsAbbVie · NCT01113931 · 495 enrolled · United States
- Mar 2, 2011Phase 4 study in RosaceaGalderma Group · NCT01308619 · 170 enrolled · United States
- Aug 26, 2011Phase 4 study in RosaceaGalderma Group · NCT01426269 · 235 enrolled · United States
- Nov 16, 2011Phase 3 study in Acne VulgarisGalderma Group · NCT01474590 · 266 enrolled · Canada
- Mar 15, 2013Phase 4 study in RosaceaGalderma Group · NCT01872715 · 24 enrolled · United States
- Oct 19, 2017Dr. Reddy's Laboratories's first study: phase 2 study in RosaceaNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT03340961 · 205 enrolled · Germany
TargetBeta
“Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 7 inhibitor; Matrix metalloproteinase 8 inhibitor”ChEMBL 37, by rule
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT03340961Rosacea · Germany | 2 | Completed | Dr. Reddy's Laboratories | Nov 7, 2018 | 205 |
| NCT01872715Rosacea · United States | 4 | Completed | Galderma Group | Jun 2013 | 24 |
| NCT01474590Acne Vulgaris · Canada | 3 | Completed | Galderma Group | Jul 2013 | 266 |
| NCT01426269Rosacea · United States | 4 | Completed | Galderma Group | Jun 2013 | 235 |
| NCT01308619Rosacea · United States | 4 | Completed | Galderma Group | Aug 2012 | 170 |
| NCT01113931Chlamydia Infections · United States | 3 | Completed | AbbVie | Oct 2010 | 495 |
| NCT00939562Bacterial Infections · India | 4 | Completed | Pfizer | Dec 2008 | 24 |
| NCT00892281Rosacea · United States | 4 | Completed | Galderma Group | Oct 2009 | 1,421 |
| NCT00829790Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 30 |
| NCT00829764Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Oct 2006 | 30 |
| NCT00775918Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Jun 2005 | 32 |
| NCT00775177Healthy · United States | – | Completed | Sun Pharmaceutical Industries | Jun 2005 | 32 |
| NCT00764361Diabetic Foot · United States | 2 | Completed | nanoshift-llc | Aug 2010 | 15 |
| NCT01380496Lecithin Cholesterol Acyltransferase Deficiency · Canada | 1 | Completed | Par Health | Nov 1999 | 24 |
| NCT01380483Fasting · Canada | 1 | Completed | Par Health | Apr 2000 | 40 |
| NCT00653380Fasting · Canada | 1 | Completed | Par Health | Oct 1999 | 24 |
| NCT00652795Fasting · Canada | 1 | Completed | Par Health | Sep 2004 | 36 |
| NCT00652704Lecithin Cholesterol Acyltransferase Deficiency · Canada | 1 | Completed | Par Health | Sep 1999 | 24 |
| NCT00649571Healthy · United States | 1 | Completed | Viatris | Jul 2005 | 35 |
| NCT00648180Healthy · United States | 1 | Completed | Viatris | Aug 2005 | 36 |
| NCT00647959Healthy · United States | 1 | Completed | Viatris | Mar 2006 | 36 |
| NCT00635609Acne Vulgaris · United States | 4 | Completed | AbbVie | Sep 2008 | 93 |
| NCT00612573Acne Vulgaris · United States | 2 | Completed | AbbVie | Nov 2008 | 257 |
| NCT00495313Rosacea · United States | 4 | Completed | Galderma Group | Dec 2007 | 91 |
| NCT00439400Dry Eye Syndromes · United States | 2 | Completed | alacrity-biosciences-inc | 160 | |
| NCT00126399Rosacea | 3 | Completed | Galderma Group | 528 | |
| NCT00041977Rosacea · United States | 3 | Completed | Galderma Group | 150 |
How it is read
Names in the registry
- “Doxycycline Monohydrate”, 7 entries
- “Doxycycline”, 5 entries
- “doxycycline monohydrate”, 5 entries
- “doxycycline”, 5 entries
- “Doxycycline monohydrate 100mg tablets”, 2 entries
Conditions, from the studies’ own filings
- Rosacea, 8 studies
- Acne Vulgaris, 6 studies
- Fasting, 3 studies
- Anthrax, 1 study
- Diabetic Foot, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.